文献速递妇科

肿瘤电场治疗联合紫杉醇治疗复发性卵巢癌:INNOVATE 先导研究结果

Tumor Treating Fields in combination with paclitaxel in recurrent ovarian carcinoma: Results of the INNOVATE pilot study.
PubMed 文献 · Gynecol Oncol · 2018-07-27

INNOVATE(EF-22)是一项 2 期单臂临床试验,在 31 例铂耐药复发性卵巢癌患者中评估肿瘤电场治疗(TTFields,200 kHz)联合每周紫杉醇(起始剂量 80 mg/m²)的安全性与疗效。主要终点为安全性;未报告与 TTFields 相关的严重不良事件,3-4 级不良事件频率与文献中单药每周紫杉醇相比未见增加。中位无进展生存期为 8.9 个月,7 例(25%)达部分缓解,临床获益率为 71%,中位总生存期未达到,一年生存率为 61%。

要点

  • 31 例铂耐药复发性卵巢癌患者接受 TTFields(200 kHz)联合每周紫杉醇治疗。
  • 未报告与 TTFields 相关的严重不良事件,3-4 级不良事件较文献单药每周紫杉醇未见增加。
  • 中位无进展生存期 8.9 个月,部分缓解 7 例(25%),临床获益率 71%。

核心结论

  • TTFields 联合每周紫杉醇在铂耐药复发性卵巢癌中安全性可接受,值得在随机 3 期试验中评估。

研究设计与样本

  • INNOVATE(EF-22)研究为 2 期单臂临床试验,纳入 31 例铂耐药复发性卵巢癌患者,评估 TTFields(200 kHz)联合每周紫杉醇的安全性与疗效。

主要发现

  • 中位年龄 60 岁(范围 45-77),24 例(77%)为浆液性组织学,16 例(52%)ECOG 评分 0,15 例(48%)ECOG 评分 1,既往化疗中位线数为 4(范围 1-11)。
  • 全部患者既往接受过铂类化疗,30 例(97%)既往接受过紫杉类药物。
  • 未报告与 TTFields 相关的严重不良事件;3-4 级不良事件频率与文献中单药每周紫杉醇相比未见增加。
  • 26 例(84%)出现预期的 TTFields 相关皮炎,仅 1 例因皮炎永久终止 TTFields。
  • 中位无进展生存期为 8.9 个月,7 例(25%)达部分缓解,临床获益率为 71%;中位总生存期未达到,一年生存率为 61%。

关键数值与推荐

  • TTFields 频率为 200 kHz。
  • 紫杉醇给药方案:每周一次,持续 8 周,之后在每个后续 28 天周期的第 1、8、15 天给药;起始剂量 80 mg/m²。
  • 主要终点为安全性;次要终点包括总生存期、无进展生存期和缓解率。

临床怎么用

  • 作者认为 TTFields 联合每周紫杉醇在铂耐药复发性卵巢癌中安全,值得在随机 3 期试验中评估。

局限性

  • 原文未报告局限性。
  • 原文结论提出值得在随机 3 期试验中评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Tumor Treating Fields (TTFields) are an anti-mitotic therapy comprising continuous delivery of low-intensity alternating electric fields at intermediate frequencies to the tumor region by a home-use medical device. METHODS: The INNOVATE (EF-22) Study was a phase 2, single arm clinical trial, which tested the safety and efficacy of TTFields (200 kHz) in combination with weekly paclitaxel (weekly for 8 weeks and then on days 1, 8, 15 of each subsequent 28 day-cycle; starting dose 80 mg/m2) in 31 patients with recurrent, platinum-resistant ovarian carcinoma. The primary endpoint was safety and secondary endpoints included OS, PFS and RR. RESULTS: Median age was 60 (range: 45-77), 24 patients (77%) had serous histology, 16 patients (52%) ECOG score 0 and 15 (48%) ECOG 1, the median number of prior chemotherapy lines was 4 (range: 1-11). All patients received prior platinum-based chemotherapy and 30 (97%) received prior taxanes. No serious adverse events related to TTFields were reported. There was no increase in grade 3-4 adverse events compared to the frequency of such events reported in the literature with single agent weekly paclitaxel. Twenty-six patients (84%) had the expected TTFields-related dermatitis but only one patient permanently discontinued TTFields due to dermatitis. The median PFS was 8.9 months, 7 patients (25%) had partial response and the clinical benefit rate was 71%. The median overall survival was not reached: the one-year survival rate was 61%. CONCLUSION: TTFields combined with weekly paclitaxel were safe in platinum-resistant recurrent ovarian cancer and warrants evaluation in a randomized phase 3 trial.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Vergote I, von Moos R, Manso L, et al. Tumor Treating Fields in combination with paclitaxel in recurrent ovarian carcinoma: Results of the INNOVATE pilot study. Gynecol Oncol. 2018. PMID: 30060963. doi:10.1016/j.ygyno.2018.07.018

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。